603079.SH
圣达生物
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 12.63
−9.98%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 830.5M | 844.5M | 827.4M | 727.4M | 738.0M |
| Cost of Revenue | 616.2M | 623.7M | 651.5M | 611.0M | 607.2M |
| Gross Profit | 214.4M | 220.9M | 175.9M | 116.5M | 130.8M |
| Operating Expenses | |||||
| R&D Expense | 53.6M | 53.7M | 43.8M | 42.9M | 37.4M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 68.3M | 65.7M | 63.8M | 62.0M | 63.2M |
| Selling & Marketing Expense | 15.1M | 15.0M | 14.6M | 14.2M | 13.2M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 145.5M | 140.5M | 123.6M | 118.1M | 100.6M |
| Cost and Expenses | 761.6M | 764.2M | 775.1M | 729.0M | 707.8M |
| Operating Income (EBIT) | 71.2M | 80.2M | 46.6M | (45.7M) | 36.1M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 71.0M | 80.1M | 49.1M | (45.3M) | 36.5M |
| Income Tax Expense | 9.8M | 10.9M | 11.8M | 8.9M | 6.1M |
| Bottom Line | |||||
| Net Income | 53.6M | 62.2M | 29.4M | (54.1M) | 31.5M |
| Earnings from Cont. Ops | 61.2M | 69.3M | 37.3M | (54.2M) | 30.4M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 53.6M | 62.2M | 29.4M | (54.1M) | 31.5M |
| Per Share | |||||
| Basic EPS | CN¥0.30 | CN¥0.35 | CN¥0.17 | (CN¥0.32) | CN¥0.18 |
| Diluted EPS | CN¥0.30 | CN¥0.35 | CN¥0.17 | (CN¥0.32) | CN¥0.18 |
| Revenue Per Share | CN¥4.41 | CN¥4.76 | CN¥4.78 | CN¥4.31 | CN¥4.22 |
| Shares | |||||
| Basic Shares Outstanding | 188.2M | 177.6M | 173.1M | 168.9M | 174.9M |
| Diluted Shares Outstanding | 188.2M | 177.6M | 173.1M | 168.9M | 174.9M |
| Profitability Metrics | |||||
| EBITDA | — | 161.6M | 125.5M | 31.7M | 108.6M |
| D&A | — | 81.4M | 79.0M | 77.4M | 72.5M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026